More Node Negative Patients Surviving Breast Cancer: Findings Reported at 2010 San Antonio Breast Cancer Symposium
Largest aromatase inhibitor TEAM trial reveals huge strides in breast cancer treatment
THE WOODLANDS, Texas, Dec. 11, 2010 /PRNewswire/ -- Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, participated in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study that included nearly 10,000 patients over a five-year period. More than 2,000 of the nearly 10,000 patients studied were treated within the US Oncology system. Dr. Jones presented the compelling study results today during a poster discussion at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.
(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)
The study titled "Competing Causes of Mortality vs. Breast Cancer Mortality at 5-years among 9766 postmenopausal women with hormone receptor positive early breast cancer treated on the TEAM study of adjuvant hormonal therapy" revealed fascinating findings.
"The TEAM trial is the largest aromatase inhibitor trial ever conducted, and it is now mature," said Dr. Jones. "At the SABCS, we have several important posters and poster discussion papers. In the one I presented, we demonstrated marked progress in the overall treatment of breast cancer so that in nearly 10,000 women followed for five years in this trial, the odds of dying from breast cancer were just slightly higher than from other unrelated causes. In fact, in node negative breast cancer, the odds of dying of other causes were greater than the risk of death from breast cancer. This is truly global progress against breast cancer as this trial was conducted in nine countries."
More compelling findings from the TEAM trial will be revealed later today as posters:
Posters: |
|
|
|
Discontinuation during tamoxifen in the sequential arm of the TEAM trial of adjuvant endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer: the effect of IES results and subsequent therapy |
|
Cornelis J. H. van de Velde, Elysee T. M. Hille, Daniel Rea, Caroline Seynaeve, Annette Hasenburg, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Dirk G. Kieback, Lina Asmar, Jan Smeets, Johan W. R. Nortier, Peyman Hadji, John M. S. Bartlett, Hein Putter, Stephen E. Jones. |
|
|
|
Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: a meta-analysis |
|
P. Hadji, L. Asmar, J.G.H. van Nes, T. Menschik, A. Hasenburg, J. Kuck, H. Nortier, S.E. Jones, M. Ziller |
|
Dr. Jones is one of several internationally recognized investigators affiliated with US Oncology Research who participated in studies that are being presented, discussed and displayed Dec. 8-12. Other leading investigators also participated in the following studies that will be displayed as posters at the conference: |
|
Posters: |
|
|
|
Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study |
|
Blum JL, Twelves CJ, Akerele C, Seegobin S, Wanders J, Cortes J. |
|
|
|
Meta-analysis of patients with triple-negative disease from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC) |
|
J O'Shaughnessy, G Romieu, V Dieras, M Byrtek, A-A Duenne, D Miles. |
|
|
|
Survival Outcomes With Eribulin vs. Treatment of the Physician's Choice (TPC) in Heavily Pretreated Patients with Locally Recurrent or Metastatic Breast Cancer in North America, Western Europe, and Australia: Results of the Phase III EMBRACE Study C. Twelves1, D. Loesch2, J. Blum3, L. Vahdat4, K. Petrakova5, X. Durando6, S. Seegobin7, C. Dutcus8 |
|
Many clinical studies led by US Oncology Research Network physicians were also predominantly featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the American Society of Hematology (ASH) Annual Meeting and Exposition.
Those studies, along with more than 30 published manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology at 281-863-1000.
About US Oncology
US Oncology, Inc. is the nation's leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with 1,400 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.
About US Oncology Research
US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation's largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled nearly 47,000 patients in more than 1,100 trials since inception in 1992 and has contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.
SOURCE US Oncology, Inc.
Share this article